Sign in

    Kelly Shee • Jefferies Financial Group Inc.

    Kelly Shi is a Senior Equity Research Analyst at Jefferies, specializing in the healthcare sector with a primary focus on biotechnology and pharmaceutical companies. She covers a range of publicly traded firms, including Immatics N.V., Heron Therapeutics, Astria Therapeutics, and others, and has generated over 40% success rates across 19 to 48 stock recommendations, with an average return per rating of approximately -4% according to third-party ranking platforms. Her career began at Jefferies, where she has developed deep sector expertise, having been quoted and featured in industry conference calls through at least 2025. Kelly is a registered securities professional and maintains applicable FINRA licenses as required for senior research analysts.

    Kelly Shee's questions to Kyverna Therapeutics Inc (KYTX) leadership

    Kelly Shee's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q3 2024

    Question

    Kelly Shee asked about the biological differentiators of targeting STAT6 compared to other pathways like IL-4, IL-13, or OX40, and what other indications the STAT6 program could pursue beyond common TH2 diseases.

    Answer

    Founder, President, and CEO Nellie Monofi and Chief Medical Officer Jared Gullop responded. Nellie highlighted that STAT6 is the central node for both IL-4 and IL-13 signaling, allowing for a more complete blockade. Jared added that STAT6 degradation may offer more sustained pathway inhibition and has shown potential to reduce itch and pain transcripts, key symptoms in atopic dermatitis.

    Ask Fintool Equity Research AI

    Kelly Shee's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q2 2024

    Question

    Kelly Shee from Jefferies asked for more specific plans regarding the upcoming Phase 1 trial for the STAT6 program, particularly concerning indication selection based on preclinical findings.

    Answer

    CEO Nello Manalfi highlighted the accelerated timeline to Phase 1. CMO Jared Golub detailed the plan for a traditional single and multiple ascending dose study in healthy volunteers. The trial will include key pharmacodynamic measures, such as STAT6 degradation in blood and skin, and TH2 biomarkers like IgE and TARC, to demonstrate pathway impact.

    Ask Fintool Equity Research AI